HOME >> MEDICINE >> NEWS
Two landmark studies show Taxotere (R) significantly improves survival in men with prostate cancer

BRIDGEWATER, NJ - June 7, 2004 - Aventis (NYSE: AVE) announced today that the results of two landmark phase III trials using Taxotere® (docetaxel) Injection Concentrate based regimens in the treatment of androgen-independent (hormone-refractory) metastatic prostate cancer have been presented at the plenary session of the annual meeting of the American Society of Clinical Oncology (ASCO) in New Orleans, LA.

The clinical trials TAX 327 and SWOG 9916, were led by investigators from the Johns Hopkins Kimmel Cancer Center and NewYork-Presbyterian Hospital/Columbia University Medical Center and the Southwest Oncology Group (SWOG). The trials involved nearly 1,800 patients and demonstrated that Taxotere®-based regimens significantly reduced the risk of death by 24 percent and 20 percent, respectively. Investigators in the TAX 327 trial also reported that Taxotere® significantly improved patients' PSA responses by 43 percent (p=0.0005) and improved pain responses by 59 percent (p=0.0107), relative to mitoxantrone response rates.

The SWOG trial investigators reported a 27 percent increase in disease-progression-free survival and a 55 percent increase in objective response rate in the Taxotere®-containing arm. In addition, the majority of patients had a PSA decline of more than 50 percent.

"These studies are the first to show that a chemotherapy agent, Taxotere®, can deliver a significant survival benefit in androgen-independent (hormone-refractory) metastatic prostate cancer patients, giving hope to thousands of men worldwide," said Daniel Petrylak, MD, Associate Professor of Medicine at Columbia University College of Physicians & Surgeons, Director of the Genitourinary Oncology Program at NewYork-Presbyterian Hospital. "These data represent an important new treatment option for men with prostate cancer because it can help some patients live longer."

Prostate cancer ranks third worldwide in cancer incidence
'"/>

Contact: Lisa Kennedy, Aventis
lisa.a.kennedy@aventis.com
908-243-6361
Porter Novelli
7-Jun-2004


Page: 1 2 3 4

Related medicine news :

1. The Hospital of the University of Pennsylvania evaluates heart failure treatments for landmark study
2. Mayo Clinic establishes landmark research program to predict and prevent alcoholism
3. UCLA seeks thousands of current and former smokers for landmark lung cancer screening trial
4. New studies suggest airborne SARS transmission is possible
5. New studies show mixed results on epilepsy drugs and birth defects
6. Brain imaging studies investigate pain reduction by hypnosis
7. Impact of scientific advances on drug studies and membrane research to be explored
8. Two studies find evidence that sunlight may have beneficial influence on cancer
9. More studies on risks and benefits of COX-2 inhibitors published in Archives of Internal Medicine
10. Animal studies show stem cells might make biological pacemaker
11. Infants, children prefer sounds over pictures and only slowly become visually oriented, studies find

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/19/2019)... SACRAMENTO, Calif. (PRWEB) , ... February 19, 2019 ... ... CommonBond as a CDA Endorsed Program that offers competitive student loan refinancing as ... largest financial hurdles a dentist may face. The average educational debt for all ...
(Date:2/19/2019)... ... February 19, 2019 , ... ClearHealth ... to Foley & Lardner LLP, as Recognized Consultants. The CHQI Recognized Consultant Program ... in pursuing CHQI accreditation. , Ms. Wein and Mr. Einhorn are part ...
(Date:2/19/2019)... ... ... According to a recent study by Columbia University, more than 40% of ... only 26% of widows return to their pre-loss level of life satisfaction, according to ... the most tragic events that one can face. Consequently, many look for a support ...
(Date:2/19/2019)... (PRWEB) , ... February 19, 2019 , ... K.J. Kidd, ... her book “Dexascan: Beyond a Missed Opportunity”: an autobiographical work offered to encourage other ... provide early detection. , Kidd shares, “On September 28th of 2013, I spent ...
(Date:2/19/2019)... ... , ... STAR Institute for Sensory Processing Disorder (SPD) is launching ... The focus of the new program is to bring like-minded professionals together in an ... will be held on Zoom for five weekly one-hour sessions on Wednesdays 8 PM ...
Breaking Medicine News(10 mins):
(Date:2/19/2019)... N.J. (PRWEB) , ... February ... ... applications and infrastructure solutions provider for global service providers, enterprises, and developers, ... and orchestration platform with the Arvizio MR Studio mixed reality visualization and ...
(Date:2/19/2019)... Md. (PRWEB) , ... February 19, 2019 , ... ... to funding research grants for Stage IV metastatic breast cancer (MBC), announces the ... to METAvivor President, Beth Fairchild, “In honor of our 10-year anniversary, we are ...
(Date:2/19/2019)... ... February 19, 2019 , ... ... completed his new book “Live Hard Die Young.” Dr. Oexner was the first ... medicine, therapeutic exercise physiology, and nutritional counseling. Dr. Oexner was a supervisor on ...
Breaking Medicine Technology:
Cached News: